Precigen (PGEN) EV/EBIT: History & Chart

Precigen, Inc.(PGEN)

Biotechnology · Germantown, MD

$7.56-0.19 (-2.39%)

Delayed quote: Oct 6, 2026, 3:50 PM EDT

About Precigen, Inc.

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.

Germantown, MD

160 employees

www.precigen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Helen Sabzevari

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Precigen, Inc. (PGEN)	$2.69B	N/A	N/A	N/A	N/A
MBX Biosciences, Inc. Common Stock (MBX)vs ›	$2.69B	N/A	N/A	N/A	N/A
AtriCure, Inc. (ATRC)vs ›	$2.73B	189.29x	169.00x	169.00x	169.00x
Acadia Healthcare Company, Inc. (ACHC)vs ›	$2.69B	15.00x	12.41x	11.52x	10.90x
Aveanna Healthcare Holdings Inc. (AVAH)vs ›	$2.67B	14.07x	12.70x	46.55x	42.04x
TransMedics Group, Inc. (TMDX)vs ›	$2.78B	38.90x	46.98x	64.49x	64.49x
Neogen Corporation (NEOG)vs ›	$2.59B	N/A	57.78x	87.55x	74.52x
Beam Therapeutics Inc. (BEAM)vs ›	$2.58B	N/A	N/A	N/A	N/A
NewAmsterdam Pharma Company N.V. (NAMS)vs ›	$2.57B	N/A	3.68x	3.68x	3.68x
Privia Health Group, Inc. (PRVA)vs ›	$2.57B	N/A	94.82x	129.24x	129.46x

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Precigen, Inc. (PGEN)

$2.69B

N/A

MBX Biosciences, Inc. Common Stock (MBX)vs ›

$2.69B

N/A

AtriCure, Inc. (ATRC)vs ›

$2.73B